TITLE:
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

CONDITION:
Carcinoma, Renal Cell

INTERVENTION:
CPG 7909

SUMMARY:

      CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is
      as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be
      included in the study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Stage IV Renal Cell Carcinoma with lung and/or soft tissue metastasis Nephrectomy
        Measurable disease by RECIST criteria

        Exclusion Criteria:

        CNS, bone or Liver metastasis Tumors that are mainly papillary, chromophobe, medullary,
        collecting duct, or unclassified Prior immunotherapy, including IL-2 or IFN-alpha
      
